The Lancet Psychiatry· 2026Q1

Association between CYP2D6 and CYP2C19 genotypes and venlafaxine treatment failure: a retrospective study on two cohorts from Norway and the UK

Yoomi Park, Hasan Çağın Lenk, Yitian Zhou, Volker M Lauschke et al.

1citations
Q1SCImago
2026year

Short summary

Individuals with CYP2D6 poor metabolizer (PM) genotypes had 2.05 times higher odds of switching antidepressants within a year compared to normal metabolizers in a Norwegian cohort, a finding replicated in a UK cohort. Dual CYP2D6 and CYP2C19 PMs showed a 6.11-fold increased risk of switching.

AI-generated from the title and abstract; the full text is not read.

TakeawaysIn the app

Key pointsIn the app

Ask the paperIn the app

The rest is in the Pofolia app

Takeaways, key points and questions to the paper; new summaries every day for your field. Free.

Get it on Google Play Download on the App Store

PharmacologyPharmacology, Toxicology and Pharmaceutics